相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
CD28-ζ CAR T Cells Resist TGF-β Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop
Viktoria Golumba-Nagy et al.
MOLECULAR THERAPY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy
Serena Pellegatta et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Chondroitin Sulfate Proteoglycan 4 and its Potential As an Antibody immunotherapy Target across Different Tumor Types
Kristina M. Ilieva et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum
Asen Bagashev et al.
MOLECULAR AND CELLULAR BIOLOGY (2018)
Tumors evading CARs-the chase is on
Sarwish Rafiq et al.
NATURE MEDICINE (2018)
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Elena J. Orlando et al.
NATURE MEDICINE (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
Therapeutic T cell engineering
Michel Sadelain et al.
NATURE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches
Amanda C. Winters et al.
FRONTIERS IN PEDIATRICS (2017)
Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy
Frida Ewald Sander et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
Dennis C. Harrer et al.
BMC CANCER (2017)
CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL
Sandra Jordaan et al.
BIOMEDICINES (2017)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein
Manal Amoury et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
An essential role for the IL-2 receptor in Treg cell function
Takatoshi Chinen et al.
NATURE IMMUNOLOGY (2016)
The Role of NG2 Proteoglycan in Glioma
Sridevi Yadavilli et al.
TRANSLATIONAL ONCOLOGY (2016)
Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy
Fabiana Perna et al.
TRANSLATIONAL CANCER RESEARCH (2016)
MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program
Jing Xu et al.
CELL DISCOVERY (2016)
Generation of CD8+ T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy
Sandra Hoefflin et al.
CANCER BIOLOGY & THERAPY (2015)
Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone
Christian Krug et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
CAR therapy: the CD19 paradigm
Michel Sadelain
JOURNAL OF CLINICAL INVESTIGATION (2015)
Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer
Pier Andrea Nicolosi et al.
THERANOSTICS (2015)
A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor
Christian Krug et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues
Hannes Brehm et al.
CANCER LETTERS (2014)
T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
Claudia Geldres et al.
CLINICAL CANCER RESEARCH (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells
Rachel E. Beard et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso et al.
BLOOD (2013)
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
Cor H. J. Lamers et al.
MOLECULAR THERAPY (2013)
CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
Zeyana Rivera et al.
CLINICAL CANCER RESEARCH (2012)
Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4
Xinhui Wang et al.
CANCER RESEARCH (2011)
Analysis of the Role of Hematopoietic Stem-Cell Transplantation in Infants With Acute Lymphoblastic Leukemia in First Remission and MLL Gene Rearrangements: A Report From the Children's Oncology Group
Zoann E. Dreyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck Activation
David M. Kofler et al.
MOLECULAR THERAPY (2011)
CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
Xinhui Wang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
Marco de Bruyn et al.
MOLECULAR CANCER (2010)
Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies
Allison S. Drake et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells
Michael Schwenkert et al.
MELANOMA RESEARCH (2008)
A new way to generate cytolytic tumor-specific T cells:: electroporation of RNA coding for a T cell receptor into T lymphocytes
Niels Schaft et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells
W. Luo et al.
ONCOGENE (2006)
Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer
U Ozerdem
PROSTATE (2006)
Targeting pericytes diminishes neovascularization in orthotopic uveal melanoma in nerve/glial antigen 2 proteoglycan knockout mouse
Ugur Ozerdem
OPHTHALMIC RESEARCH (2006)
Malignant hematopoietic cell lines:: in vitro models for the study of MLL gene alterations
HG Drexler et al.
LEUKEMIA (2004)
Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia:: close association with MLL rearrangement and a CD10-/CD24-/CD65s+/CD15+ B-cell phenotype
S Schwartz et al.
LEUKEMIA (2003)
Tumor-specific T cell activation by recombinant immunoreceptors:: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can ge integrated into one combined CD28/CD3ζ signaling receptor molecule
A Hombach et al.
JOURNAL OF IMMUNOLOGY (2001)
Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1
C Wuchter et al.
LEUKEMIA (2000)
Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma
JM Tordsson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2000)
分享论文
